Sign in
Taking people in NorwayPhase 3

Avatrombopag compared with rituximab for immune thrombocytopenia after steroid treatment

Compares avatrombopag and rituximab in adults with immune thrombocytopenia not helped enough by corticosteroids.

Key facts

Who runs it
Ostfold Hospital Trust
Where
Bergen, Bodo, Fredrikstad, Haugesund, Kristiansand S, Levanger, Loerenskog, Oslo, Stavanger, Tonsberg, Tromsoe, and Trondheim, NorwaySee the 12 sites
Registry title
Comprehensive Evaluation of Two Second-Line Therapeutic Approaches for Immune Thrombocytopenia (ITP) – a Pragmatic Randomized Controlled Trial - Holistic Study
Status
Recruiting
Phase
Phase 3
People taking part
220 people, planned
Started
1 Jul 2025
Expected to end
31 Dec 2027
Type of study
Interventional
Record updated
15 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with primary immune thrombocytopenia (ITP, a low platelet count caused by the immune system) whose disease did not respond well enough to a short course of corticosteroids. It compares Avatrombopag with Rituximab.

Age
18 years and older
Sex
Male or female
Disease stage
Primary ITP diagnosed less than one year ago. The doctor must judge that more treatment to raise platelets is needed.
Earlier treatment
At least one course of dexamethasone (20-40 mg daily for 4 days) or prednisone/prednisolone (1 mg/kg for at least two weeks), with no response or a relapse. Shorter or lower courses count if stopped or changed due to side effects. Ongoing corticosteroids are allowed. People cannot join after earlier Rituximab, other immune suppressants, dapsone, danazol, chemotherapy (except vincristine as rescue) or spleen removal. Short thrombopoietic agent use (at most 2 weeks, not in the last two weeks) is allowed.
Biomarker or test result
Platelet count below 30 x109/L measured within two weeks before joining.

Main reasons for not taking part

  • ITP caused by another disease, such as lymphoma, CLL, lupus, antiphospholipid syndrome, CVID, HIV or hepatitis C
  • Active hepatitis B (positive HBsAg), cirrhosis or severe liver problems
  • Active cancer, apart from some listed minor or early forms
  • Severe heart failure, serious infections or a severely weakened immune system
  • Pregnancy or breastfeeding, or refusing effective birth control

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Male or female aged ≥18 years
  • Diagnosis of primary ITP of less than one-year duration and having a platelet count of < 30 x109/L measured within two weeks prior to inclusion with failure to achieve response or relapse after at least one cycle of dexamethasone (20-40 mg daily for 4 days) or prednisone /prednisolone (1 mg/kg for at least two weeks). Shorter courses or lower doses are allowed if discontinued or modified due to side effects
  • Failure to achieve response or relapse after at least one cycle of dexamethasone (20-40 mg daily for 4 days) or prednisone /prednisolone (1 mg/kg for at least two weeks). Shorter courses or lower doses are allowed if discontinued or modified due to side effects. Ongoing treatment with corticosteroids is allowed at the time of inclusion
  • Clinical need for subsequent platelet elevating therapy assessed by the physician in charge
  • Signed and dated written informed consent

Who cannot take part

  • Females of child-bearing potential refusing to follow effective contraceptive methods (as described in SmPC) for at least 12 months following the last administration of Rituximab or during treatment with Avatrombopag
  • Concomitant autoimmune hemolytic anemia
  • Known allergy, sensitivity or contraindication to Rituximab or Avatrombopag
  • Any contraindication according to the SmPC of Rituximab (e.g. active serious infections (e.g. tuberculosis, opportunistic infections, sepsis) and serious heart failure (NYHAC IV) or serious uncontrolled heart disease) or of Avatrombopag (e.g. cirrhosis and/or severe hepatic impairment).”
  • Presence of active malignancy unless deemed cured by adequate treatment. Participants with the following neoplastic conditions can be included: a. Monoclonal gammopathy of undetermined significance (MGUS) or monoclonal B lymphocytosis of undetermined significance (MBUS). b. Basal/squamous cell carcinoma of the skin c. Carcinoma in situ of the cervix d. Carcinoma in situ of the breast e. Incidental histological finding of prostate cancer (TNM stage T1a or T1b)
  • Patients with history of poor compliance or history of alcohol/drug abuse or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or any disease that might interfere with the ability to comply with the study protocol or give informed consent
  • Secondary ITP: ITP secondary to lymphoma or chronic lymphocytic leukemia; ITP secondary to the following autoimmune disorders: Systemic Lupus Erythematosus, or Antiphospholipid Syndrome; ITP secondary to Common Variable Immune Deficiency; ITP secondary the following viral infections: Human Immunodeficiency Virus or Hepatitis C Virus
  • Active hepatitis B virus (positive HBsAg). Patients with HBsAg negative and HBV core antibody positive (HBcAb) should accept to receive entecavir (Baraclude) for 12 months if they will be allocated to Rituximab. Monthly HBV DNA monitoring will be required while on treatment and for the 6 months after the last dose of the study drug
  • Presence of any serious comorbidity where the condition may worsen by the study drugs
  • Previous treatment for ITP with: Rituximab, other immune suppressants than corticosteroids e.g. mycophenolate mofetil, azathioprine, cyclosporine), dapsone, danazol, chemotherapy (apart from vincristine as rescue therapy) or splenectomy. Short treatment with any thrombopoietic agent is allowed if given for a limited duration of a maximum of 2 weeks and not given within the last two weeks before inclusion, as rescue therapy for quick elevation of platelet count in emergency situations e.g. high risk of bleeding or ongoing bleeding or surgery
  • Patients in a severely immune compromised state
  • Pregnancy or lactation

Where in Norway

  • Helse Bergen HFBergen, NorwayTaking people
  • Nordlandssykehuset HFBodo, NorwayTaking people
  • Ostfold Hospital TrustFredrikstad, NorwayTaking people
  • Helse Fonna HFHaugesund, NorwayTaking people
  • Sorlandet Sykehus HFKristiansand S, NorwayTaking people
  • Nord-Trondelag Hospital TrustLevanger, NorwayTaking people
  • Akershus University HospitalLoerenskog, NorwayTaking people
  • Oslo University Hospital HFOslo, NorwayTaking people
  • Helse Stavanger HFStavanger, NorwayTaking people
  • Vestfold Hospital TrustTonsberg, NorwayTaking people
  • University Hospital Of North Norway HFTromsoe, NorwayTaking people
  • St. Olavs hospital HFTrondheim, NorwayTaking people

About the trial

What the trial wants to find out

To compare in a randomized clinical trial (RCT) the efficacy of the oral TPO-RA, Avatrombopag, to Rituximab, in adult ITP patients who fail to achieve adequate response (does not respond, relapse or cannot discontinue corticosteroids after 6 week from initiation) to a short course of corticosteroids.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Comprehensive Evaluation of Two Second-Line Therapeutic Approaches for Immune Thrombocytopenia (ITP) – a Pragmatic Randomized Controlled Trial - Holistic Study
Plain-language title
Avatrombopag compared with rituximab for immune thrombocytopenia after steroid treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
15 September 2026